Crystallization of Amorphous Indomethacin during Dissolution: Effect of Processing and Annealing
Authors:
- 11 May 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 7 (5) , 1406-1418
Abstract
The crystallization of amorphous drugs during dissolution is a type of solution mediated phase transformation that can reduce the bioavailability enhancement one hoped to gain from the amorphous state. The goal of this study was to explore the effects of processing on the dissolution performance of amorphous indomethacin. The amorphous solids were prepared by four techniques, quench cooling the melted solid, cryogrinding γ indomethacin amorphous for 1 or 3 h and quench cooling the solid followed by 1 h of cryogrinding. Dissolution results assessed in a flow-through intrinsic dissolution apparatus reveal decreases in the dissolution rate of amorphous indomethacin during the experimental time frame indicating that a solution mediated phase transformation has occurred. The amorphous solids prepared by melt quenching and melt quenching followed by cryogrinding showed a significant dissolution rate advantage over the γ form of indomethacin. In contrast, indomethacin that was cryoground amorphous for 1 or 3 h did not show any dissolution rate advantage over the crystalline material. Transformation was confirmed by in situ Raman microscopy and polarized light microscopy with differences seen in the nature of the crystals apparent on the surface of the dissolving solid. A portion of the melt quenched amorphous sample was annealed at 25 °C and 0% relative humidity to induce partial crystallization of γ indomethacin. As crystallinity increased, the dissolution rate decreased. The transformation time of partially amorphous indomethacin was not dependent on the level of crystallinity present, indicating only a small fraction of crystalline material needs to be present to affect the kinetics of crystallization. The solution mediated phase transformation of amorphous indomethacin is affected by the processing method even though all solids were confirmed amorphous by polarized light microscopy and X-ray diffraction. Dissolution may distinguish differences in amorphous solids that other methods cannot discern.Keywords
This publication has 46 references indexed in Scilit:
- Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysisJournal of Pharmaceutical Sciences, 2010
- Design and characterization of a laminar flow-through dissolution apparatus: Comparison of hydrodynamic conditions to those of common dissolution techniquesPharmaceutical Development and Technology, 2010
- Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic millingInternational Journal of Pharmaceutics, 2009
- Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopyJournal of Pharmaceutical and Biomedical Analysis, 2006
- Phase transformation considerations during process development and manufacture of solid oral dosage formsAdvanced Drug Delivery Reviews, 2004
- Fluorescence studies of the transformation of carbamazepine anhydrate form III to its dihydrate phaseJournal of Pharmaceutical Sciences, 2004
- A mechanistic study of danazol dissolution in ionic surfactant solutionsJournal of Pharmaceutical Sciences, 2003
- Quantitative FT-Raman analysis of two crystal forms of a pharmaceutical compoundJournal of Pharmaceutical and Biomedical Analysis, 1997
- Some physicochemical properties of glassy indomethacin.Chemical and Pharmaceutical Bulletin, 1986
- Dissolution at porous interfaces V. Pore effects in a parallel-plate dissolution cellInternational Journal of Pharmaceutics, 1983